Author:
Riviere-Cazaux Cecile,Graser Christopher J.,Warrington Arthur E.,Hoplin Matthew D.,Andersen Katherine M.,Malik Noor,Palmer Elizabeth A.,Carlstrom Lucas P.,Dasari Surendra,Munoz-Casabella Amanda,Ikram Samar,Ghadimi Keyvan,Himes Benjamin T.,Jusue-Torres Ignacio,Sarkaria Jann N.,Meyer Fredric B.,Van Gompel Jamie J.,Kizilbash Sani H.,Sener Ugur,Michor Franziska,Campian Jian L.,Parney Ian F.,Burns Terry C.
Abstract
ABSTRACTWhile serial sampling of glioma tissue is rarely performed prior to recurrence, cerebrospinal fluid (CSF) is an underutilized longitudinal source of candidate glioma biomarkers for understanding therapeutic impacts. However, the impact of key variables to consider in longitudinal CSF samples, including anatomical location and post-surgical changes, remains unknown. To that end, pre- versus post-resection intracranial CSF samples were obtained at early (1-16 days; n=20) or delayed (86-153 days; n=11) timepoints for patients with glioma. Paired lumbar-versus-intracranial glioma CSF samples were also obtained (n=14). Using aptamer-based proteomics, we identify significant differences in the CSF proteome between lumbar, subarachnoid, and ventricular CSF. Our analysis of serial intracranial CSF samples suggests the early potential for disease monitoring and evaluation of pharmacodynamic impact of targeted therapies. Importantly, we found that resection had a significant, evolving longitudinal impact on the CSF proteome. Proteomic data are provided with individual clinical annotations as a resource for the field.One Sentence SummaryGlioma cerebrospinal fluid (CSF) accessed intra-operatively and longitudinally via devices can reveal impacts of treatment and anatomical location.
Publisher
Cold Spring Harbor Laboratory
Reference61 articles.
1. Glioma;Nature Reviews Disease Primers,2015
2. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
3. Glioma Grading: Sensitivity, Specificity, and Predictive Values of Perfusion MR Imaging and Proton MR Spectroscopic Imaging Compared with Conventional MR Imaging;American Journal of Neuroradiology,2003
4. J. D. Bernstock , S. E. Gary , N. Klinger , P. A. Valdes , W. Ibn Essayed , H. E. Olsen , G. Chagoya , G. Elsayed , D. Yamashita , P. Schuss , F. A. Gessler , P. Paolo Peruzzi , A. K. Bag , G. K. Friedman , Standard clinical approaches and emerging modalities for glioblastoma imaging. Neuro-Oncology Advances 4, (2022).
5. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults